clinical trial · NCT04658862
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Janssen Research & Development, LLC·phase3·active not recruiting·n = 518
Urinary Bladder NeoplasmsCetrelimabTAR-200CisplatinGemcitabineConventional radiation therapyHypo-fractioned radiation therapy
brief summary
The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.
started
Dec 7, 2020
primary completion
Dec 30, 2026
completion
Dec 31, 2028
last updated
Jun 5, 2026
official title
A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol